Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP-211 Dose Ranging Study in Type 2 Diabetes
NCT07546929Phase 2Recruiting
- Sponsor
- Housey Healthcare
- Start
- Feb 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of axulin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Housey Healthcare. Primary endpoint: Hemoglobin A1c at 12 weeks. Started Feb 2023; status: recruiting.
02
Drugs
axulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07546929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546929.